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SINCE THE FIRST ANTIRETROVIRALdrug was approved 25 years ago,improvements in the potency,tolerability, simplicity, and avail-
ability of antiretroviral therapy (ART)
have resulted in dramatically reduced
numbers of opportunistic diseases and
deaths where ART is accessible.1 New
data show that viral suppression due to
ART results in decreased human immu-
nodeficiencyvirus (HIV) transmissionon
individual2 and population levels1 and
that, when used consistently by HIV-
uninfected persons, ART also may pro-
vide protection against HIV infec-
tion.3-5 Together, these developments
have translated into newly articulated vi-
sions of the “beginning of the end of
AIDS.”6 This revision of the Interna-
tional Antiviral (formerly AIDS) Society–
USA (IAS-USA) guidelines reflects new
data informing consideration of when to
initiate ART, new options for initial and
Context New trial data and drug regimens that have become available in the last 2
years warrant an update to guidelines for antiretroviral therapy (ART) in human immu-
nodeficiency virus (HIV)–infected adults in resource-rich settings.
Objective To provide current recommendations for the treatment of adult HIV in-
fection with ART and use of laboratory-monitoring tools. Guidelines include when to
start therapy and with what drugs, monitoring for response and toxic effects, special
considerations in therapy, and managing antiretroviral failure.
Data Sources, Study Selection, and Data Extraction Data that had been pub-
lished or presented in abstract form at scientific conferences in the past 2 years were sys-
tematically searched and reviewed by an International Antiviral Society–USA panel. The
panel reviewed available evidence and formed recommendations by full panel consensus.
Data Synthesis Treatment is recommended for all adults with HIV infection; the strength
of the recommendation and the quality of the evidence increase with decreasing CD4
cell count and the presence of certain concurrent conditions. Recommended initial regi-
mens include 2 nucleoside reverse transcriptase inhibitors (tenofovir/emtricitabine or aba-
cavir/lamivudine) plus a nonnucleoside reverse transcriptase inhibitor (efavirenz), a ritonavir-
boosted protease inhibitor (atazanavir or darunavir), or an integrase strand transfer inhibitor
(raltegravir). Alternatives in each class are recommended for patients with or at risk of
certain concurrent conditions. CD4 cell count and HIV-1 RNA level should be monitored,
as should engagement in care, ART adherence, HIV drug resistance, and quality-of-care
indicators. Reasons for regimen switching include virologic, immunologic, or clinical fail-
ure and drug toxicity or intolerance. Confirmed treatment failure should be addressed
promptly and multiple factors considered.
Conclusion New recommendations for HIV patient care include offering ART to all
patients regardless of CD4 cell count, changes in therapeutic options, and modifica-
tions in the timing and choice of ART in the setting of opportunistic illnesses such as
cryptococcal disease and tuberculosis.
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subsequent therapy, ART management
in the setting of special conditions, and
new approaches to monitoring treat-
ment success and quality. Discussion of
the emerging area of antiretroviral pre-
exposure prophylaxis for high-risk HIV-
seronegative persons is included.
discussions for each section. Prior to se-
lection of teams and leaders, panel mem-
bers declared and discussed potential
conflicts of interests and recused them-
selves from serving as section leaders or
team members, accordingly.
The panel limited recommendations
to HIV-infected adults in international
resource-rich settings with ART that was
available (approved by regulatory bod-
ies or in expanded access) or in late-
stage development (New Drug Applica-
tion filed). Recommendations were made
by full panel consensus and rated ac-
cording to the strength of the recom-
mendation and the quality of the sup-
porting evidence (eBox; available at http:
//www.jama.com). For areas in which
recommendations have not changed sub-
stantially or no or few new data are avail-
able, the previous report is referenced.7
WHEN TO START
All adults with HIV infection should be
offered ART regardless of CD4 cell
count, based on recent observational co-
hort data that all patients may benefit
from ART and data from a random-
ized controlled trial showing that ART
reduces the likelihood of HIV trans-
mission while providing clinical ben-
efit to treated individuals.2 When pre-
scribing ART, the following should be
considered: (1) a patient must be ready
and willing to adhere to ART, and ad-
herence education and support should
be offered9; (2) the benefit of ART is un-
known in elite controllers (HIV-1 RNA
below the level of quantification with-
out ART) and long-term nonprogres-
sors (those with stable CD4 cell counts
500/µL and HIV-1 RNA 1000 cop-
ies/mL while not taking ART); (3) the
benefit of ART in asymptomatic acute
HIV infection is not as well studied as
in symptomatic acute HIV infection;
and (4) there is no CD4 cell count
threshold at which starting therapy is
contraindicated, but the strength of the
recommendation and the quality of the
evidence supporting initiation of
therapy increase as the CD4 cell count
decreases and when certain concur-
rent conditions are present (BOX 1).
Established HIV Infection
In addition to the previously de-
scribed data,7 recent evidence increas-
ingly supports earlier initiation of ART.
Although no randomized controlled
trial defines the optimal time of initia-
tion, available data are consistent with
and further strengthen the recommen-
dation for early ART.
In the HIV-CAUSAL collaboration,
there was a significant and steady de-
crease in AIDS-free survival as the CD4
cell count threshold for initiation of
therapy decreased. There was an esti-
mated 38% increase in the hazard
of AIDS or death when therapy was
initiated below a CD4 cell count of
350/µL compared with 500/µL.10 The
CASCADE seroconversion cohort, with
more than 9000 study participants, con-
firmed the benefits of starting ART be-
low 500 CD4 cells/µL.11 The COHERE
study of 75 336 individuals examined
the prognostic value of the CD4 cell
count after virologic suppression by
ART and noted that higher CD4 cell
count was associated with incremen-
tal decreases in the risk of new AIDS
events, all-cause mortality, and non-
AIDS mortality across all CD4 cell strata
up to 500/µL and a slightly reduced risk
of disease progression above 500/µL.12
Similarly, other cohort studies noted
that the higher the CD4 cell count
achieved after ART, the greater the sur-
vival benefit, implying that starting ART
earlier may lead to improved out-
comes.13,14 In the Athena cohort,14 older
age, lower CD4 cell nadir, and lower
plasma HIV-1 RNA at the start of ART
were independent predictors of poor
immunologic recovery, leading to
increased morbidity and mortality. Fur-
thermore, the HIV Prevention Trials
Network (HPTN) 052 study of 1763
HIV-serodiscordant couples with CD4
cell counts between 350/µL and 550/µL
showed that immediate initiation of
therapy resulted in a 41% reduction in
serious World Health Organization
stage 4 events, pulmonary tuberculo-
sis (TB), serious bacterial infections, and
death.2 Because the study was con-
ducted largely in low- and middle-
income countries, the clinical end-
METHODS
A systematic literature review using 
PubMed and EMBASE was conducted 
to identify relevant evidence pub-
lished since the last report.7 Data pre-
sented at scientific conferences in ab-
stract form or released as safety reports 
by regulatory agencies or data and safety 
monitoring boards also were consid-
ered. Specified search terms included 
HIV and antiretroviral and treatment (or 
prevention or toxicity or monitoring) and 
filters included dates (July 1, 2010, to 
May 25, 2012), English, humans, 
adults, clinical trial OR meta-analysis 
OR guidelines OR editorials OR re-
view, and full text OR free text OR ab-
stracts. More than 600 potentially re-
lated articles were identified, of which 
141 were determined to be relevant. 
Panel  members  conducted  hand  
searches for newly published reports, 
abstracts from scientific conferences, 
and safety reports throughout the 
guideline development process; manu-
facturers of antiretroviral drugs pro-
vided lists of published, presented, and 
safety data, which were cross-checked 
with search results. Data that were not 
published or presented in a peer-
reviewed setting were not considered. 
Recommendations were developed by 
an international panel established ini-
tially by the IAS-USA in 19958 with 
planned member rotations. Members are 
experts in HIV research and clinical care 
and serve in a volunteer (noncompen-
sated) capacity. Members do not partici-
pate in industry promotional activities 
such as speaker bureaus, lectures, or 
other marketing activities during their 
membership on the panel. The current 
panel convened in January 2012 and met 
twice weekly by teleconference. Sec-
tion leaders (J.A.A., J.F.H., A.T., and 
P.A.V.) and teams were appointed to 
evaluate evidence and summarize panel
pointanalysiswasdrivenpredominantly
by TB.
In a registry of 20 775 HIV-infected
and 215 158 uninfected persons, the in-
cidence of most cancers was either no
longer elevated in HIV-infected per-
sons with CD4 cell counts at or above
500/µL compared with HIV-unin-
fected persons or was greatly de-
creased, also supporting earlier initia-
tion of ART.15 Several cross-sectional
studies examining the effect of CD4 cell
count nadir on surrogate markers of
cardiovascular risk suggest benefit for
early therapy, although studies prov-
ing that ART can decrease this risk are
lacking at this time.16-18
The concentration of HIV in both
blood and seminal plasma correlates
with the probability of transmission of
HIV to a sexual partner.19 Reducing lev-
els of HIV with ART decreases the prob-
ability of transmission,19 as confirmed
in the HPTN 052 study, in which ART
was 96% effective in reducing HIV
transmission.2 Reduction of transmis-
sion has also been shown in high-risk
men who have sex with men,20 al-
though viral suppression in plasma does
not guarantee suppression in semen, es-
pecially in the presence of inflamma-
tion.21 Additionally, other sexually
transmitted infections such as hepati-
tis C virus (HCV)22 and syphilis23 con-
tinue to be reported at high rates, es-
pecially in men who have sex with men,
underscoring the importance of con-
tinued condom use.
Several communities with high ART
use have observed an association be-
tween reduced “community viral loads”
and lower rates of new infections.24,25
The use of HIV treatment as preven-
tion addresses an important public
health objective, especially in the ab-
sence of a vaccine or additional inex-
pensive, highly effective prevention
strategies other than condom use and
male circumcision. Fortunately, the ex-
panding recommendations for nearly
universal treatment of HIV-infected per-
sons in resource-rich countries and
some middle-income countries ren-
der the recommendations for treat-
ment of the individual concordant with
public health goals. Challenges in-
clude limited financial and workforce
resources, the need to implement
broader testing, and the need for im-
proved strategies to enhance engage-
ment in HIV care and adherence to
ART.
Special Considerations
Pregnancy. ART is indicated for all preg-
nant women to prevent HIV transmis-
sion to the infant and for the mother’s
health. Those not yet taking ART should
start fully suppressive therapy as soon
as possible. The potential for nonad-
herence due to morning sickness should
not be an impediment to starting
therapy.26,27 Women who conceive while
already taking ART, including efa-
virenz or tenofovir, should continue the
same therapy unless there is a need for
change due to failure or intolerance.
Therapy should not be discontinued
post partum.
Opportunistic Infections. Early ini-
tiation of ART is recommended after
starting active treatment of opportunis-
tic infections. However, implementa-
tion may require focused educational
and logistical support28,29 and consider-
ation of the potential for drug interac-
tions requiring dosage alterations.
Box 1. Recommendations for When to Initiate Antiretroviral
Therapy (ART)a
Patient readiness for treatment should be considered when deciding to initiate ART.
Clinicians should engage supportive services as needed to assist with ART educa-
tion and to address barriers to adherence (AIII).
ART is recommended and should be offered regardless of CD4 cell count (AIa-
CIII). The strength of the recommendation increases as CD4 cell count decreases
and in the presence of certain conditions, with the following ratings:
For CD4 cell count of 500/µL and below: AIa
For CD4 cell count above 500/µL: BIII
Ratings for specific conditions are as follows:
Pregnancy: AIa
Chronic hepatitis B virus (HBV) coinfection: AIIab
Hepatitis C virus (HCV) coinfection: CIII (however, coinfection with CD4 cell
count 500/µL may delay ART until after completion of HCV treatment)
Age older than 60 years: BIIa
Human immunodeficiency virus (HIV)-associated nephropathy: AIIa
ART is recommended and should be offered to persons during the acute phase of
primary HIV infection, regardless of symptoms (BIII).b
ART should be started as soon as possible, preferably within the first 2 weeks of
diagnosis, in patients with opportunistic infections (AIa). The optimal timing for
patients with cryptococcal meningitis is less certain, but initiating ART early dur-
ing cryptococcal treatment may be associated with higher mortality; therefore, ART
initiation in these patients should be managed in consultation with experts (BIII).
ART is recommended in all HIV-infected persons with tuberculosis (TB) and should
be started within 2 weeks of TB treatment when the CD4 cell count is below 50/µL
and by 8 to 12 weeks for those with higher CD4 cell counts (A1a). The optimal tim-
ing for patients with TB meningitis is less certain, but ART should be started within
the first 2 to 8 weeks of diagnosis and managed in consultation with experts (BIII).
aRatings of the strength of the recommendations and quality of evidence are described in
the eBox.
bThese recommendations differ from some HBV treatment guidelines that require both high-
level HBV replication and necroinflammation. However, HBV liver disease progresses more
rapidly in HIV-infected persons and the safety of the low necroinflammatory state is less well
established than in persons without HIV.
in the immediate ART group had sig-
nificantly more severe adverse events.35
Whether these results also can be gen-
eralized is unclear because the patient
population included a high propor-
tion of injection drug users with un-
derlying viral hepatitis; most deaths oc-
curred in the first month of treatment,
before an effect of ART could be ob-
served; and risk of death was related to
severity of TB meningitis.35 Therefore,
early initiation of ART should be con-
sidered in persons with HIV and TB
meningitis, but with close monitoring
and management in consultation with
experts, particularly if CD4 cell count
is below 50/µL.
Hepatitis B Virus. The risk of liver-
related morbidity and mortality is in-
creased in persons dually infected with
HIV and hepatitis B virus (HBV).7 Al-
though there are conflicting data as to
whether HBV adversely affects the natu-
ral history of HIV,36 the potential to treat
both infections with the same medica-
tions provides a compelling argument
for treatment of all HIV- and HBV-
coinfected persons who otherwise have
no contraindications to therapy.
Hepatitis C Virus. Infection with
HIV also increases the risk of liver-
related morbidity and mortality in per-
sons dually infected with HCV.7 In some
but not all studies, treatment of HIV re-
duces progression of HCV-related liver
disease.37,38 It is also possible that ART
improves the response to HCV treat-
ment by improving immune function.
However, most of the evidence that
HCV treatment might be more effec-
tive in persons receiving ART is based
on lower responses to HCV therapy in
persons with CD4 cell counts below
500/µL. That observation and interac-
tions between ARV drugs and the cur-
rently available HCV drugs might pro-
vide a justification to delay ART until
after completion of HCV treatment in
patients with CD4 cell counts greater
than 500/µL.
Older Age and HIV-Associated
Nephropathy. As previously recom-
mended, age older than 60 years is an
indication to start ART regardless of
CD4 cell count.7 Persons with HIV-
associated nephropathy should begin
therapy as soon as the diagnosis is made
because ART improves survival and kid-
ney function in these patients.39,40
Acute HIV Infection. ART initia-
tion has been recommended for those
with symptomatic acute HIV infec-
tion.7 In the absence of definitive data
from randomized controlled trials on
the risks and benefits of treating asymp-
tomatic primary infection, several ar-
guments can be made for initiating ART
during acute and early infection.
Early treatment has been associated
with reduced lymphoid tissue pathol-
ogy, conserved lymphocyte func-
tion,41 lowered cell-associated HIV-1
DNA,42 and a transient reduction of vi-
ral set point after treatment interrup-
tion.43 Randomized clinical trials of im-
mediate vs deferred ART for recently
infected individuals have shown a de-
layed rate of CD4 cell decline after treat-
ment interruptions of 6 to 15 months
compared with deferred treatment.44,45
A substantial proportion of ongoing
HIV transmission is attributable to in-
dividuals with acute infection.46-48 These
individuals may have markedly higher
HIV-1 RNA levels in plasma and geni-
tal secretions, which increases the risk
of transmission per sexual encounter.
Thus, offering persons with acute HIV
infection early treatment represents a
high priority in ART-for-prevention
strategies.
WHAT TO START
The options for initial therapy for treat-
ment-naive adults with confirmed drug-
susceptible virus continue to expand,
with new drugs and coformulations
(TABLE 1 and TABLE 2). Because therapy
is expected to be sustained indefi-
nitely, regimen choice must consider
patient convenience, potential toxici-
ties, and tolerability that may affect ad-
herence. The aim of therapy contin-
ues to be maximal, lifelong, and
continuous suppression of HIV repli-
cation to prevent emergence of resis-
tance, facilitate optimal immune recov-
ery, and improve health. Interactions
among ART drugs and with other medi-
cations are a growing challenge as per-
Recent data have raised concerns 
about the timing of ART initiation dur-
ing cryptococcal meningitis. In a ran-
domized clinical trial conducted in Zim-
babwe, ART was begun within 72 hours 
after diagnosis of cryptococcal menin-
gitis or delayed until completion of 10 
weeks of antifungal treatment with 800 
mg/d of fluconazole alone. The risk of 
death was 2.85 times higher in the early 
ART group.30 Immune reconstitution in-
flammatory syndrome (IRIS) oc-
curred in patients in both groups and 
did not explain the increased mortal-
ity. The increased mortality seen in the 
early ART treatment group is concor-
dant with the recent announcement of 
the cessation of randomization in the 
COATS trial following data and safety 
monitoring board review.31 Antifungal 
therapy consisted of fluconazole alone 
in the former study and amphotericin 
B plus fluconazole during induction fol-
lowed by fluconazole alone in the 
COATS study. These data suggest that 
persons with HIV and cryptococcal 
meningitis should be closely moni-
tored after starting ART and managed 
in consultation with experts, particu-
larly if CD4 cell counts are below 50/µL. 
Three randomized trials evaluating 
when to start ART during TB treat-
ment demonstrated that early ART im-
proved AIDS-free survival compared 
with initiation after completion of TB 
treatment. The greatest benefit was 
achieved in persons with CD4 cell 
counts below 50/µL, and for this sub-
group, the optimal time of ART initia-
tion was within the first 2 weeks of TB 
treatment.32-34 Those with higher CD4 
cell counts who deferred ART until 8 
to 12 weeks after starting TB treat-
ment had lower rates of IRIS and other 
adverse events. In all 3 studies, trends 
toward improved AIDS-free survival 
were observed across all CD4 cell count 
strata. Benefit was greatest in those with 
most advanced immunosuppression, as 
were rates of IRIS. Deaths attributable 
to IRIS were few. In a randomized trial 
of 253 patients with HIV and TB men-
ingitis, initiation of ART within 2 vs 8 
weeks of TB treatment was not associ-
ated with improved survival, and those
sons with HIV age and require addi-
tional medications for comorbid
conditions.49-51 The cost of therapy is
expected to be an increasingly impor-
tant issue as part of a larger movement
to control health care expenditures. Ge-
neric ART drugs may reduce program
costs and allow for treatment of more
individuals, but it will be crucial to en-
sure that any resulting medication
choices do not revert to older and more
toxic drugs no longer recommended in
these guidelines. Also, more complex
regimens without coformulated drugs
raise adherence concerns and may in-
crease out-of-pocket costs in regions
where patients have co-payments for
each prescription.52
Initial therapy continues to be based
on a combination of 2 nucleos(t)ide re-
verse transcriptase inhibitors (NRTIs)
and a potent third agent, generally a
nonnucleoside reverse transcriptase in-
hibitor (NNRTI), a ritonavir-boosted
protease inhibitor (PI/r), an integrase
strand transfer inhibitor (InSTI), or,
rarely, an agent that blocks the CC
chemokine receptor 5 (CCR5). For each
component of a regimen, specific situ-
ations can dictate different recom-
mended and alternative agents (Table 1
and Table 2). There is no evidence that
drug efficacy differs among different
subtypes of HIV-1.53 Coformulations of
drugs and complete regimens in fixed-
dose combinations (FDCs) increas-
ingly used once daily are preferred for
convenience and probable improved
medication adherence.7,52,54 As addi-
tional potent and well-tolerated drugs
become available, interest is growing in
regimens that do not include NRTIs, but
sufficient evidence is lacking to recom-
mend them as initial regimens. Some
older drugs are still available but have
essentially no role in initial ART and
will not be discussed herein.
Nucleos(t)ide Reverse
Transcriptase Inhibitors
Three 2-drug NRTI FDCs are cur-
rently available. In some cases, these
FDCs are coformulated with another
potent drug, adding to the overall regi-
men convenience.
Recommended. Tenofovir diso-
proxil fumarate and emtricitabine are
available in a once-daily FDC with no
food restrictions. Tenofovir is well tol-
erated but has been associated with kid-
ney injury, which appears to increase
in incidence with long-term adminis-
tration and concurrent PI/r use.16,55,56
Table 2. CCR5 Antagonist–Based and NRTI-Sparing Initial Regimens That Can Be Considered









Tropism assay to confirm R5 virus
should be done before
prescribing maraviroc. Maraviroc
is not effective in persons who
have X4 or dual/mixed X4/R5
virus infection. Few data are









Data emerging for these regimens.
Clinical trial evidence needed
before formal recommendation
can be made.
Abbreviations: CCR5, CC chemokine receptor 5; InSTI, integrase strand transfer inhibitor; NRTI, nucleos(t)ide reverse
transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; /r, ritonavir-
boosted.
aRatings of the strength of the recommendations and quality of evidence are described in the eBox.
Table 1. Recommended and Alternative Initial Antiretroviral Regimens, Including Strength of Recommendations and Quality of Evidencea
Recommended Regimens Alternative Regimensb Comments
NNRTI plus NRTIs Efavirenz/tenofovir/emtricitabine (AIa)
Efavirenz plus abacavir/lamivudinec,d
(AIa) in HLA-B*5701–negative
patients with baseline plasma





(or rilpivirine plus abacavir/
lamivudine) (BIa)
Severe hepatotoxicity and rash with
nevirapine are more common in
initial therapy when CD4 cell
count is 250/µL in women and
400/µL in men.





(AIa) in patients with plasma






Other alternative PIs include
fosamprenavir/r and saquinavir/r
but indications to use these
options for initial treatment
are rare.






Raltegravir is given twice daily;
experience with
elvitegravir/cobicistat/tenofovir/
emtricitabinee is limited to
48-week data.
Abbreviations: InSTI, integrase strand transfer inhibitor; NRTI, nucleos(t)ide reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibi-
tor; /r, ritonavir-boosted.
aRatings of the strength of the recommendations and quality of evidence are described in the eBox. Fixed-dose combinations are recommended when available and appropriate.
Current fixed-dose combinations available are efavirenz/tenofovir/emtricitabine; tenofovir/emtricitabine; abacavir/lamivudine; rilpivirine/tenofovir/emtricitabine; lopinavir/ritonavir;
zidovudine/lamivudine; and, if approved, elvitegravir/cobicistat/tenofovir/emtricitabine.
bZidovudine/lamivudine is an alternative NRTI component of NNRTI-, PI/r-, and raltegravir-based regimens, but the toxicity profile of zidovudine reduces its utility.
cHLA-B*5701 screening is recommended before abacavir administration to reduce the risk of hypersensitivity reaction.
dAvoiding the use of abacavir or lopinavir/ritonavir might be considered for patients with or at high risk of cardiovascular disease.
eNew Drug Application for this combined formulation has been filed with regulatory authorities. Approval decisions pending.
Renal function should be assessed be-
fore use and monitored over time,57 dos-
ing adjusted according to the package
insert in the case of renal impairment
(estimated glomerular filtration rate
[eGFR] 50 mL/min), and tenofovir
discontinued when eGFR is below 30
mL/min. Tenofovir causes a decrease in
bone mineral density in the spine and
hip,58,59 the long-term progression of
which currently remains ill defined.
Emtricitabine is similar to lamivudine
in mechanism of action, potency, tox-
icity, and patterns of resistance.
An abacavir and lamivudine FDC of-
fers once-daily administration, no food
restriction, and minimal subjective tox-
icity. Screening for HLA-B*5701 mark-
edly reduces the risk of potentially life-
threatening hypersensitivity reaction to
abacavir.7 In some studies60,61 but not
in others,62-65 abacavir has been asso-
ciated with a higher risk of acute myo-
cardial infarction.
Initial regimens containing abacavir/
lamivudine had lower rates of viral sup-
pression in persons with baseline HIV-1
RNA levels above 100 000 copies/mL
than regimens containing tenofovir/
emtricitabine.7 However, in a second
randomized trial, this difference was not
observed.66 Lamivudine is extremely
well tolerated.
Alternatives. A zidovudine and la-
mivudine FDC must be used twice daily.
Zidovudine commonly causes head-
ache, nausea, anemia, neutropenia, and
progressive and persistent peripheral li-
poatrophy. Its use should be reserved




a rash, which usually but not always re-
solves despite continued treatment.
Alternatives. Nevirapine is now avail-
able in a 400-mg once-daily formula-
tion. Nevirapine requires a 2-week
lead-in of 200 mg once daily.69 Rash is
more common and usually more severe
than with efavirenz. Severe hepatotox-
icity is occasionally seen with initial use.
Both severe rash and hepatotoxicity are
more common with baseline CD4 cell
counts above 250/µL in women and
400/µL in men.
Rilpivirine is administered once daily.
In 2 studies, rilpivirine was noninfe-
rior to efavirenz, although rates of vi-
rologic failure were higher with rilpi-
virine while rates of adverse events were
higher with efavirenz.70,71 Virologic fail-
ure was more common in patients with
baseline HIV-1 RNA above 100 000 cop-
ies/mL, and rilpivirine should be
avoided in this population. Rilpivirine
has substantial food interactions and
should be taken with at least a 400-
kcal meal. Concomitant use of rilpiv-
irine and proton-pump inhibitors is
contraindicated.
Protease Inhibitors
Protease inhibitors are used in combi-
nation with 2 NRTIs as part of initial
ART. The bioavailability of PIs re-
quires coadministration with a drug
such as ritonavir that augments or
“boosts” levels of the PI through inhi-
bition of the CYP34A enzyme. An-
other drug with this property, cobici-
stat, is being developed.72 As a class, PIs
are associated with mild to moderate
nausea, diarrhea, and dyslipidemia. All
PIs may be associated with cardiac con-
duction abnormalities, particularly PR
interval prolongation.73 A baseline elec-
trocardiogram and avoidance of other
agents causing prolonged PR or QT in-
tervals should be considered.
Recommended. Ritonavir-boosted
atazanavir is used in initial therapy once
daily. It blocks bilirubin conjugation,
resulting in a nearly universal eleva-
tion in unconjugated (indirect) biliru-
bin. Usually modest, this can cause vis-
ible jaundice in some individuals but
does not represent hepatotoxicity.
Atazanavir requires gastric acidity for
absorption and should be taken with
meals and with avoidance of proton-
pump inhibitors; if used, proton-
pump inhibitors should be taken dis-
tant from the time of atazanavir/r
administration. Unboosted atazanavir
has reduced potency and is not recom-
mended. Atazanavir may be associ-
ated with nephrolithiasis and in 1 study
was associated with renal dysfunc-
tion.74 Atazanavir is the only PI/r shown
to be noninferior to efavirenz-based
therapy in a large randomized trial.75
Darunavir must be boosted to be ac-
tive. Ritonavir-boosted darunavir is used
once daily in initial regimens and
should be taken with a meal to im-
prove bioavailability. Darunavir con-
tains sulfa and may produce hypersen-
sitivity reactions, especially in those
with sulfa allergy.
Alternatives. Lopinavir is available
only as an FDC with ritonavir. Fewer
individuals randomized to lopinavir/r
in combination with tenofovir/
emtricitabine maintained HIV-1 RNA
below 50 copies/mL at 48 and 96 weeks
vs those randomized to darunavir/r or
atazanavir/r.7 Ritonavir-boosted lopi-
navir causes more frequent gastroin-
testinal adverse effects than other PIs.
It can be used once daily and does not
require administration with food.
Fosamprenavir or saquinavir boosted
with ritonavir may be used once daily,
taken with a meal, in initial therapy.
Fosamprenavir contains a sulfa moi-
ety and may cause rash. In 1 random-
ized trial, once-daily saquinavir/r was
noninferior to atazanavir/r and had
comparably mild adverse effects.76
Integrase Strand Transfer Inhibitors
The newest drug class of potent antiret-
roviral drugs used with a dual NRTI
backbone, the InSTIs are well tolerated.
Similar to NNRTIs, current InSTIs have
a low genetic resistance barrier.
Recommended.Raltegravir shouldbe
used twicedaily, asonce-dailydosingdi-
minishes efficacy.77 Raltegravir does not
requireconcomitant foodconsumption.
Alternative. A once-daily coformu-
lation of tenofovir, emtricitabine, el-
Nevirapine, efavirenz, and rilpivirine are 
each available as a single pill for once-
daily use; the 2 latter drugs are avail-
able in FDCs with tenofovir and em-
tricitabine.
Recommended. Efavirenz is used 
once daily, preferably without food at 
bedtime. Central nervous system ad-
verse effects include sleep disturbance, 
abnormal dreams, and, less commonly, 
depressed mood.67,68 Efavirenz can cause
vitegravir, and cobicistat is pending
regulatory approval in the United States
for treatment-naive patients.78 Elvite-
gravir is an investigational InSTI pend-
ing regulatory approval in the United
States for treatment-experienced pa-
tients.79 It requires boosting to achieve
sufficient potency. Cobicistat is an in-
vestigational pharmacokinetic booster
pending regulatory approval in the
United States that can cause substan-
tial drug-drug interactions. Cobicistat
causes an immediate and reversible
small increase in serum creatinine and
eGFR without actually affecting mea-
sured creatinine clearance because it
competes with excretion of creatinine
by the kidney.80 When substantial or
progressive increase in serum creati-
nine occurs, evaluation of kidney func-
tion and adjustment of the regimen
should be considered.
Attachment Inhibitors
Drugs that block CCR5 have durable
antiretroviral activity only if the indi-
vidual is infected with HIV that uses
CCR5 exclusively and not CXCR4. The
use of these drugs thus requires recep-
tor tropism screening. The pheno-
typic assay that measures tropism is ex-
pensive and time-consuming, but
genotypic tropism testing is faster,
cheaper, and may facilitate the use of
such drugs.81 Maraviroc is the only cur-
rently approved CCR5 attachment in-
hibitor. It is used twice daily and has
no food restrictions.
Special Considerations
Pregnancy. The choice of ART in preg-
nant women should take into consider-
ation the same benefits and risks as in all
HIV-infected adults as well as any spe-
cial considerations associated with the
pregnancy. The Antiretroviral Preg-
nancy Registry of more than 15 000 HIV
exposures (January 1989–July 2011)
notes no increase in rates of congenital
birth defects with exposure to ART, in-
cluding efavirenz, even in the first tri-
mester.82
Comorbid Diseases. Preexisting risks
or existence of particular comorbidi-
ties influence the choices among oth-
erwise equally effective recommended
initial regimens. Comorbidities may be
exacerbated by the potential toxicity of
individual ART drugs and may be sub-
ject to drug-drug interactions with treat-
ments needed for such conditions.51
Cardiovascular, Renal, and Bone
Diseases. Abacavir, lopinavir/r, and
fosamprenavir/r each have been asso-
ciated with an increased risk of cardio-
vascular disease (CVD) in some60,61 but
not all62,63 studies. Such associations
have not been found for tenofovir, efa-
virenz, nevirapine, or atazanavir/r.60,83
Data on CVD risks are not yet avail-
able for darunavir/r, raltegravir, rilpiv-
irine, or elvitegravir. In persons at high
risk of CVD, avoiding abacavir, lopi-
navir/r, and fosamprenavir/r might be
considered. In patients with reduced re-
nal function, prolonged use of tenofo-
vir is associated with cumulative neph-
rotoxicity56,74 and should be avoided.
Prolonged use of atazanavir/r and lopi-
navir/r is also associated with cumula-
tive loss of renal function.55,74
Compared with uninfected individu-
als, persons with HIV infection are at
increased risk of osteoporotic fragility
fractures. In addition to traditional fac-
tors associated with bone loss, use of
tenofovir and lopinavir/r are indepen-
dent risk factors for fractures in some
but not all recent studies.59,84 Al-
though all initial ART regimens are as-
sociated with a reduction in bone min-
eral density during the first year of
treatment, the effect is more pro-
nounced with tenofovir-containing regi-
mens.58,85 Notably, in postmenopausal
women, both HIV infection and teno-
fovir use are independently associated
with higher rates of bone loss.86 Given
their increased risk of fragility frac-
tures, it may be prudent to consider
avoiding tenofovir as part of initial
therapy in postmenopausal women.
Opportunistic Infections. Drug in-
teractions and tolerability are key con-
siderations in the context of acute op-
portunistic infections. Drug interactions
with triazole antifungal drugs and those
associated with rifamycins are among
the most important. The recom-
mended initial ART regimen in the set-
ting of rifampin-based TB therapy is efa-
virenz plus NRTIs. Data are conflicting
about the effect of rifampin coadmin-
istration on efavirenz concentrations.
Early studies reported a 26% reduc-
tion in efavirenz exposure,87 but more
recent studies in patients with HIV and
TB coinfection have not shown a clini-
cally significant effect of rifampin on
efavirenz exposure.33,34,88,89 Although the
prescribing information for efavirenz in-
dicates the dosage should be in-
creased to 800 mg/d for patients weigh-
ing more than 50 kg who are being
treated with rifampin, the current FDC
with 600 mg of efavirenz is associated
with good HIV and TB outcomes re-
gardless of weight.33,34,88,90 If efavirenz
cannot be used, rifabutin-based TB
therapy with a PI/r plus NRTIs is rec-
ommended. Rifabutin reportedly has
little effect on atazanavir/r91 or lopinavir/
r,92 results in only modest increases in
darunavir,93 and has no clinically mean-
ingful effect on raltegravir.94 However,
serum concentrations of rifabutin and
its major metabolite are markedly in-
creased by all PI/rs, requiring dosage ad-
justment of rifabutin in this setting. Ri-
fabutin, 150 mg every other day,
resulted in increased rates of acquired
rifamycin resistance when used with a
PI/r regimen95,96 and lower-than-
expected concentrations of rifabu-
tin.92 Additional clinical trials are un-
der way, but in the interim, rifabutin,
150 mg/d, is suggested when used with
a PI/r regimen, and patients should be
closely monitored. Raltegravir concen-
trations are decreased when coadmin-
istered with rifampin; if a raltegravir-
based ART regimen is used, the
raltegravir dosage should be increased
to 800 mg twice daily or rifabutin
should be substituted for rifampin, but
neither approach has been evaluated in
patients with HIV and TB coinfection.
The recent recommendation for use of
a 3-month, once-weekly regimen of iso-
niazid with rifapentine for treatment of
latent TB infection is not recom-
mended for HIV-infected patients re-
ceiving ART.97
Cirrhosis. In persons with cirrhosis
but without encephalopathy, coagula-
background. If renal insufficiencyoccurs
in HBV- and HIV-coinfected persons, a
reduced dose of tenofovir, but not of the
othercomponents in the regimen, canbe
used. Entecavir has been used safely in
coinfected patients but has impaired
activityagainst lamivudine-resistantHBV
and can select for M184V in HIV reverse
transcriptase.98 In persons without
lamivudine-resistantHBV,entecavir is an
alternative to tenofovir ifusedwitha fully
suppressiveantiretroviral regimen.Treat-
ment of coinfected patients with regi-
mens containing lamivudine or emtri-
citabineas theonlyantiviralswithactivity
against HBV provides suboptimal effi-
cacy and usually results in NRTI-
resistant HBV.99,100 Interferon alfa is
approved for treatment of chronic HBV
infection but has not been rigorously
tested in HIV-coinfected persons.
Hepatitis C Virus. Peginterferon alfa
and ribavirin have been routinely used
in HIV- and HCV-coinfected persons.
Ribavirin cannot be used with didano-
sine and has overlapping toxicity with
zidovudine. It is not clear whether
peginterferon alfa plus ribavirin is less
effective when used with abacavir than
with tenofovir. The addition of the HCV
PIs telaprevir or boceprevir to pegin-
terferon alfa and ribavirin improves
treatment responses for genotype 1
chronic HCV infection.101,102 Like-
wise, preliminary phase 2 data in HIV-/
HCV-coinfected persons showed supe-
rior responses in those randomized to
peginterferon alfa, ribavirin, and bo-
ceprevir or telaprevir compared with
peginterferon alfa, ribavirin, and pla-
cebo.103,104 As phase 3 studies are on-
going and US Food and Drug Admin-
istration (FDA) approval is pending for
coinfected patients, the superior re-
sponses suggest either telaprevir or bo-
ceprevir should be added to peginter-
feron alfa/ribavirin when treating
genotype 1 chronic HCV infection.
Drug-drug interactions between te-
laprevir or boceprevir and antiretrovi-
ral drugs may alter the optimal choice
of ART when their use is anticipated.
Data from clinical trials continue to
evolve but are currently insufficient to
guide firm recommendations about rec-
ommended regimens. Available data
suggest that tenofovir, emtricitabine,
raltegravir, and etravirine may be safely
used with boceprevir, and these drugs
and rilpivirine, atazanavir/r, and efa-
virenz (with increased telaprevir dose)
may be used with telaprevir. However,
HIV and HCV RNA levels should be
carefully monitored when coadminis-
tering these drugs, and evolving data on
drug-drug interactions should be con-
sidered.105
Malignancy. Concomitant use of an-
ticancer drugs and ART is associated
with overlapping toxicities and the po-
tential for substantial drug interac-
tions due to elimination using CYP450
routes of metabolism. Raltegravir-
based regimens may be considered in
this setting because of their favorable
drug interaction profile.106 Recommen-
dations for initial regimen in the above
specific circumstances are summa-
rized in BOX 2.
MONITORING
Suppression of plasma HIV-1 RNA to
less than 50 copies/mL by 24 weeks
should occur with effective therapy, re-
gardless of prior treatment experi-
ence. No recent work has defined the
optimal frequency of monitoring in re-
source-rich economies, despite the per-
ception that such research could lead
to substantial cost savings.107 There-
fore, previous recommendations for fre-
quency of CD4 cell count and HIV-1
RNA monitoring have not changed.7
Recently introduced third-genera-
tion HIV-1 RNA assays show a lower
limit of quantification of 40 or 20 cop-
ies/mL and can report qualitative RNA
detection below these cutoffs. In
addition, many patients receiving stable
suppressive treatment show residual
viremia of 1 to 10 copies/mL using
research-based assays. The source, sig-
nificance, and optimal management of
detectable viremia of less than 50 cop-
ies/mL during treatment are poorly de-
fined. Recent studies indicate that
detectable HIV-1 RNA below the 50-
copies/mL threshold predicted re-
bound; however, the lower the viral
load, the less likely it is to result in con-
Box 2. Recommendations





In patients with or at high risk of car-
diovascular disease, avoiding use of
abacavir, ritonavir-boosted lopina-
vir, or ritonavir-boosted fosam-
prenavir might be considered (BIIa).
In patients with reduced renal func-
tion, tenofovir should be avoided, or
if treatment for hepatitis B virus
(HBV) coinfection is needed, dos-
ing should be adjusted according to
the prescribing information (AIIa).
Given the increased risk of fragility
fractures, it may be prudent to avoid
tenofovir as part of initial therapy in
postmenopausal women (BIIa).
The recommended initial ART regi-
men in the setting of rifampin-
based tuberculosis treatment is efa-
virenz plus 2 nucleos(t)ide reverse
transcriptase inhibitors (NRTIs)
(AIa).
The recent recommendation for use
of a 3-month, once-weekly regimen
of isoniazid with rifapentine for treat-
ment of latent TB infection is not rec-
ommended for human immunode-
ficiency virus (HIV)–infected patients
receiving ART (BIII).
The ART regimen for HIV- and HBV-
coinfected persons should include
tenofovir and emtricitabine (or la-
mivudine) as the NRTI background
(AIIa).
aRatings of the strength of the recom-
mendations and quality of evidence are
described in the eBox.
tion disorders, or liver synthetic abnor-
malities, there are no restrictions on 
ART. In persons with hepatic failure, 
HIV PIs and selected other antiretro-
viral drugs should be avoided or used 
with caution.
Hepatitis B Virus. The optimal ART 
regimenforHIV-andHBV-coinfectedper-
sons should include tenofovir and emtri-
citabine (or lamivudine) as the NRTI
firmed rebound.108,109 Evolution of vi-
ral resistance can occur in the setting
of low-level viremia. In 2 clinical trials
and a cohort analysis, new resistance
mutations were detected in 37% and
65%, respectively, of participants who
developed persistent low-level vire-
mia.110,111 There is lack of consensus on
management of patients with HIV-1
RNA levels between 50 and 200 copies/
mL. The AIDS Clinical Trials Group
definition of virologic failure (con-
firmed detectable HIV-1 RNA 200
copies/mL after virologic suppres-
sion) is commonly used.112 However,
the optimal management of these pa-
tients has not been determined.
There is limited evidence that ART
modifications have an appreciable im-
pact for patients with residual HIV-1
RNA levels between 1 and 10 copies/
mL.113 In practice, it is recommended
that a detectable HIV-1 RNA level dur-
ing therapy should be confirmed in a
subsequent sample, usually drawn
within 2 to 4 weeks, prior to making
management decisions. However, the
optimal interval before repeating the
HIV-1 RNA test after low-level vire-
mia occurs has not been determined,
and guidance about management strat-
egies awaits further evidence.113
Publisheddata suggest that thepreva-
lence of transmitted drug resistance
has remained stable worldwide and av-
erages 11% in Europe and 15% in North
America.114 The presence of transmitted
drug resistance may be underestimated
if a resistance test is not performed early
in infection. Although some mutations
may persist in the long term (such as re-
sistance mutations to NNRTIs), others
(suchasM184V)thatconfer impairedfit-








failure, resistance testing is essential and
should, when possible, be performed
while thepatient is still receiving the fail-
ing regimen.7
Therapeutic drug monitoring is not
recommended for general care. How-
ever, it may be useful in pregnant
women, children, and patients with re-
nal or liver impairment to minimize
overexposure and adverse effects.
Therapeutic drug monitoring also may
serve to assess adherence or to evalu-
ate virologic failure in the absence of
resistance. Therapeutic drug monitor-
ing may be useful if HCV PIs (telapre-
vir or boceprevir) must be used with
ART for which the drug interactions are
either not clarified or are known to
cause substantially increased or de-
creased exposure of 1 of the drugs.
Awareness of the potential for drug in-
teractions with these agents is impor-
tant.105,116,117
Increasing attention has been fo-
cused on determinants, measurements,
and interventions to improve entry into
and retention in care and monitoring of
and interventions to improve ART ad-
herence. Recent recommendations have
covered these issues.9 National initia-
tives118 have generated quality-of-care in-
dicators, including in the area of fol-
low-up of patients receiving treatment.
An important quality-of-care factor is
management by physicians experi-
enced in HIV medicine.119,120 Recom-
mendations for monitoring are summa-
rized in BOX 3.
TREATMENT-EXPERIENCED
PATIENTS
New regimens for ART-experienced pa-
tients should include the most active
drugs available based on genotypic
analysis, treatment and adverse effect
history, and availability of additional
classes of drugs.
Initial Virologic Failure
Management of virologic failure of an
initial regimen is usually straightfor-
ward, and a new regimen with 3 active
drugs can generally be constructed. The
regimen should be changed promptly
on confirmation of virologic failure.
Initial NNRTI-Based Regimens. De-
laying a treatment change allows the ac-
cumulation of additional NNRTI resis-
tance mutations that may limit future
treatment options with etravirine and
rilpivirine. Generating a new regimen
with 3 active agents is attainable using
a PI/r and active NRTIs. If choice is lim-
Box 3. Recommendations for




virus (HIV) 1 RNA levels should be
monitored at least every 3 months af-
tertreatmentis initiatedorchangedfor
virologicfailuretoconfirmsuppression
of viremia below 50 copies/mL (AIa).
CD4 cell count should be moni-
tored at least every 3 months after ini-
tiation of therapy, especially among
patients with less than 200/µL, to de-
termine the need for primary oppor-
tunistic infection prophylaxis (BIII).
Once viral load is suppressed for 1 year
and CD4 cell count is stable at 350/µL
or greater, HIV-1 RNA and CD4 cell
count can be monitored at intervals of
up to 6 months in patients with de-
pendable adherence (CIII).
Detectable HIV-1 RNA (50 copies/
mL) during therapy should be con-
firmedinasubsequentsamplebetween
2 and 4 weeks afterward and prior to
making management decisions (BIII).
SustainedelevationofHIV-1RNAbe-
tween 50 and 200 copies/mL should
promptevaluationof factors leadingto
failureandconsiderationof switching
of antiretroviral therapy (ART) (BIII).
Baseline genotypic testing for resis-
tance should be performed in all treat-
ment-naivepatients (AIIa) and incases
of confirmed virologic failure (AIa).
Therapeutic drug monitoring is not
recommended in routine care; how-
ever, selected patients might ben-
efit from this intervention (BIII).
Health care practitioners and health
systems should initiate strategies to
monitor and improve entry into and
retention in care and ART adher-
ence and to incorporate and ana-
lyze quality-of-care indicators (CIII).
aRatings of the strength of the recom-
mendations and quality of evidence are
described in the eBox.
vitegravir. The entry inhibitor enfuvir-
tide also was used successfully in sal-
vage regimens but is poorly tolerated
because of injection site reactions. Ma-
raviroc was used effectively in those
with CCR5-tropic HIV in combina-
tion with other active or partially ac-
tive drugs in salvage regimens. In pa-
tients with MDR HIV and no treatment
option with a regimen containing 2 ac-
tive drugs, continuation of some NRTIs,
such as lamivudine or emtricitabine
and/or tenofovir, might be considered
for continuation in a regimen, even if
resistance is present, because residual
activity of these compounds has been
demonstrated in this setting.123 Expert
advice should be sought in the setting
of MDR virus.
Dolutegravir, an InSTI currently in
development, appears to have good ac-
tivity against raltegravir- and elvitegra-
vir-resistant virus, but reduced suscep-
tibility has been reported for virus with
the Q148 or G140 signature muta-
tions.124 It is administered once daily in
the absence of integrase mutations and
twice daily when integrase mutations
are present. It does not require boost-
ing. An expanded access program for
dolutegravir provides access to drugs
for patients with documented resis-
tance to raltegravir and elvitegravir and
who are unable to construct a viable
new background regimen with com-
mercially available medications
(http://www.dolutegravir-eap.com/).
Treatment interruption is not rec-
ommended outside of clinical trials,
apart from very short interruptions due
to surgery, severe illness, or serious
drug toxicity. Studies have shown either
no benefit or inferior clinical and viro-
logic outcomes.7,125 For planned short
treatment interruptions, the different
half-lives of the individual compo-
nents of ART regimens may require a
staggered cessation of treatment.7
Immunologic Failure
There is no consensus definition of im-
munologic failure, which encom-
passes patients who are unable to
achieve adequately protective CD4 cell
count increases despite durable viro-
logic suppression with ART. Higher risk
of morbidity (due to AIDS and serious
non-AIDS events) and mortality are re-
ported in those with poor immuno-
logic recovery despite virologic sup-
pression.14 A number of strategies to
improve CD4 cell count responses have
been evaluated with no consistent ben-
efit, including switching of NRTIs or
class of drugs126 and treatment inten-
sification.127-129 Currently, there is no
immune-based therapy that has shown
a clinical benefit.130
Switching for Toxicity or Improved
Tolerability and Adherence
Switching regimens to reduce toxic-
ity, improve adherence and tolerabil-
ity, and avoid drug interactions in vi-
rologically suppressed patients can be
done by switching 1 or more agents in
the regimen. Switches of single agents
for acute or chronic toxicity are pos-
sible in patients with virologic suppres-
sion, as long as regimen potency is
maintained. Although switching from
enfuvirtide to raltegravir in virologi-
cally suppressed patients with MDR was
not associated with virologic re-
bound,7 switching a PI/r to raltegravir
has shown conflicting results,131,132 pri-
marily associated with the activity of the
background regimen.
In virologically suppressed patients
with efavirenz intolerance or toxicity,
substitution with nevirapine or rilpiv-
irine133,134 is possible. There was no in-
creased risk of nevirapine-induced
hepatotoxicity or rash at high CD4 cell
count at the time of the switch from efa-
virenz to nevirapine.135 The rilpivirine
switch can be accomplished with a ril-
pivirine/tenofovir/emtricitabine FDC.
Changing efavirenz to a PI/r or InSTI
is another approach. There are fewer
supporting data for switching to a ma-
raviroc-based regimen in virologically
suppressed individuals. Some virologi-
cally suppressed patients may require
switching of regimen components ow-
ing to anticipated drug interactions such
as with chemotherapy, treatment for TB,
or need for proton-pump inhibitors or
HCV PI therapy. If dose modification
and therapeutic drug monitoring are
ited by resistance, HLA-B*5701 posi-
tivity, or adverse reactions, use of agents 
from other classes such as InSTIs and 
CCR5 inhibitors are options.
Initial PI/r-Based Regimens. The dif-
ference between initial virologic fail-
ure of an NNRTI-based vs a PI/r-based 
regimen is that the presence of NNRTI 
resistance mutations is likely in the for-
mer; protease mutations are rarely ob-
served at the time of treatment failure 
with recommended initial PI/r regi-
mens.7 If the NRTI backbone is com-
promised, NNRTIs, raltegravir, or el-
vitegravir should be used with caution. 
Darunavir/r is associated with a lower 
incidence of virologic failure than lopi-
navir/r in treatment-experienced pa-
tients.121 There are no trials directly 
comparing darunavir/r and atazana-
vir/r in treatment-experienced pa-
tients.
Initial Raltegravir-Based Regimens. 
There are several available treatment op-
tions with 3 fully active drugs from 
classes not used in an initial raltegravir-
based regimen. Standard genotypic tests 
do not include the integrase region, and 
there are cost and access issues for in-
tegrase resistance assays. Raltegravir and 
elvitegravir are almost completely cross-
resistant. With high-level raltegravir re-
sistance, there is no clinical benefit from 
continuing raltegravir. Prompt discon-
tinuation of these drugs in a failing regi-
men increases the potential utility of the 
investigational drug dolutegravir (see 
below).
Multidrug-Resistant Virologic Failure
Following virologic failure of second 
and later regimens, the presence of mul-
tidrug-resistant (MDR) HIV is likely. 
Occasionally, patients with transmit-
ted drug resistance to 3 classes require 
initiation of therapy with drugs not in-
cluded in the above recommended ini-
tial regimens. Effective regimens usu-
ally include a PI/r with activity against 
resistant strains, usually darunavir/r. 
This can be combined with etravirine 
depending on the NNRTI resistance 
mutations detected.122 Raltegravir has 
substantial benefit in patients with MDR 
HIV. Fewer data are available for el-
not possible (see “Monitoring” sec-
tion), then switching the antiretrovi-
ral drug anticipated to cause the prob-
lem is appropriate.
Preemptive or reactive changes for
short- and long-term toxic effects such
as metabolic abnormalities136 and pre-
vention or management of lipodystro-
phy, cardiovascular risk,137 and renal
impairment have been used success-
fully with maintenance of virologic
suppression.7
Regimens that avoid NRTIs are cur-
rently being investigated and may be
considered in circumstances where rec-
ommended or alternate regimens are
contraindicated. Selection of compo-
nents should be guided by resistance
testing.
Simplification
A number of strategies have been ex-
plored for regimen simplification in vi-
rologically suppressed patients. Reduc-
tion in pill burden using FDCs or
decreasing regimen dosing frequency to
improve or maintain adherence has been
used successfully, and a meta-analysis
has confirmed better adherence for once-
daily vs twice-daily regimens.138 Not all
dose frequency reductions effectively
maintain virologic suppression in treat-
ment-experienced patients; raltegravir
once-daily dosing was inferior to twice-
daily dosing in a study of simplifica-
tion from PI/r based regimens.139 Once-
daily dosing of darunavir/r is effective
in treatment-experienced patients




egy of initiating therapy with 2 NRTIs
and a PI/r until virologic suppression
is achieved, with subsequent continu-
ation with PI/r monotherapy alone, has
been evaluated for lopinavir/r and
darunavir/r. A darunavir/r mono-
therapy maintenance strategy re-
ported good efficacy, but concern about
poor central nervous system penetra-
tion persists, with reports of discor-
dant plasma and cerebrospinal fluid vi-
ral loads.7,141 This also was observed in
a randomized trial of lopinavir/r mono-
therapy maintenance.142 At this point,
there are insufficient data to support
PI/r monotherapy owing to higher rates
of virologic failure than for combina-
tion therapy.143 Recommendations for
treatment-experienced patients are
summarized in BOX 4. Selected new rec-
ommendations since the last report7 are
summarized in BOX 5.
EMERGING ISSUES:
PREEXPOSURE PROPHYLAXIS
The field of HIV transmission preven-
tion has dramatically changed since the
last published guidelines.7 In addition
to crucial modes including behavioral
change, condoms for men and women,
male circumcision, and access to safe
injecting methods, strategies based on
antiretroviral drugs have gained ground
based on important clinical trials. ART
can prevent mother-to-child transmis-
sion and has a role in postexposure pro-
phylaxis. Antiretroviral-containing vagi-
nal and anal gels and other formulations
are also being studied, though no com-
mercially available products are avail-
able. Recently, ART used as oral pre-
exposure prophylaxis (PrEP) has been
shown to be effective in 3 large trials
using daily tenofovir/emtricitabine or
tenofovir in gay and bisexual men and
transgender women (iPrEx),3 hetero-
sexual HIV-serodiscordant couples
(Partners PrEP),4 and heterosexual men
and women (TDF2).5 A PrEP trial in
high-risk women (FEM-PrEP)144 and
one with an oral daily tenofovir group
(VOICE)145 failed to show benefit (al-
though the tenofovir/emtricitabine
treatment group of VOICE is continu-
ing). The degree of efficacy of PrEP in
these trials had an overall positive cor-
relation with medication adherence,
particularly as measured by drug lev-
els. Pharmacokinetic and pharmaco-
dynamic variability and the presence of
vaginal or rectal inflammation also may
affect outcome. Following publica-
tion of the iPrEX results, the Centers
for Disease Control and Prevention is-
sued interim guidance for manage-
ment of HIV-seronegative men who
have sex with men who elect to take te-
nofovir/emtricitabine for prophylaxis.
An update to this document is ex-
pected should the FDA approve the ap-







and Quality of Evidencea
In the setting of confirmed viro-
logic failure, changing to a new regi-
men should occur promptly, with
consideration of potential contribu-
tory factors to prevent further evo-
lution of drug resistance (AIIa).
A new regimen should be con-
structed using resistance testing (both
past and present), treatment history,
and consideration of tolerability and
adherence issues (A1a).




Management of multidrug resis-
tance is complex and expert advice
should be sought (BIII).
In virologically suppressed pa-
tients, switching single agents for tox-
icity or prevention of anticipated ad-
verse reactions or drug interactions
is generally safe and effective (A1a).
Intensification of or switching
therapy has not been successful in
improving suboptimal CD4 cell
count responses in the setting of du-
rable virologic suppression and is not
recommended (A1a).
Treatment interruptions (outside of






tor monotherapy is associated with
an increased risk of virologic failure
and is not recommended when other
options are available (A1a).
aRatings of the strength of the recom-
mendations and quality of evidence are
described in the eBox.
score the role of treatment in the pre-
vention of new HIV infections.
Although it is crucial to intensify ef-
forts to find a cure for persons who are
already infected and an effective vac-
cine for those who are not, many of the
tools needed to control the HIV/AIDS
pandemic are already at hand. Critical
components of the toolkit to eradicate
AIDS include expanded HIV testing, in-
creased focus on engagement in HIV
care, early and persistent access to ART,
and attention to improving ART adher-
ence. These must occur in the context
of strategies to address social determi-
nants of health, including the elimina-
tion of stigma and discrimination. Al-
though preventing and treating HIV are
cost-effective, current economic reali-
ties demand bold steps to ensure that
ART and quality medical care are glob-
ally accessible for all persons with HIV
and that advances in prevention also be-
come broadly available as their effica-
cies are proven.
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Box 5. Summary of Selected New Recommendations and Those for Which Strength or Quality
of Evidence Has Changed Substantiallya
Antiretroviral therapy (ART) is recommended and should be
offered regardless of CD4 cell count (A1a-CIII depending on
CD4 cell count and existing conditions).
ART is recommended and should be offered to persons during
the acute phase of primary human immunodeficiency virus
(HIV) infection, regardless of symptoms (BIII).
ART should be started as soon as possible, preferably within
the first 2 weeks of diagnosis, in patients with opportunistic
infections (other than cryptococcal and tuberculous meningi-
tis), with attention to drug interactions and the potential for
immune reconstitution inflammatory syndrome (AIa).
The optimal timing of ART initiation in patients with crypto-
coccal meningitis is less certain, but initiating ART early dur-
ing cryptococcal treatment may be associated with higher mor-
tality; therefore, ART initiation in patients with cryptococcal
meningitis should be managed in consultation with experts
(BIII).
ART is recommended in all HIV-infected persons with tuber-
culosis (TB) and should be started within 2 weeks of TB treat-
ment when CD4 cell count is below 50/µL and by 8 to 12 weeks
for those with higher CD4 cell counts (A1a). The optimal tim-
ing for patients with TB meningitis is less certain, but ART should
be started within the first 2 to 8 weeks of TB treatment and man-
aged in consultation with experts (BIII).
Abacavir/lamivudine (in patients with HIV-1 RNA levels
100 000 copies/mL) is now a recommended rather than al-
ternative dual nucleoside reverse transcriptase inhibitor (NRTI)
component of initial ART (AIa).
Rilpivirine has been added as an alternative NNRTI compo-
nent of the initial regimen (BIa).
Coformulated elvitegravir/cobicistat/tenofovir/emtricitabine has
been added as an initial regimen component, pending regula-
tory approval (BIb). Elvitegravir is an investigational inte-
grase strand transfer inhibitor and cobicistat is an investiga-
tional pharmocokinetic booster.
Given increased risk of fragility fractures in postmenopausal
women, it may be prudent to consider avoiding tenofovir as
part of initial therapy in this group (BIIa).
The recommended initial ART regimen in the setting of rifampin-
based TB therapy is efavirenz plus 2 NRTIs (AIa).
The recent recommendation for use of a 3-month, once-
weekly regimen of isoniazid with rifapentine for treatment of
latent TB infection is not recommended for HIV-infected pa-
tients receiving ART (BIII).
Sustained elevation of plasma HIV-1 RNA between 50 and 200
copies/mL should prompt evaluation of factors leading to fail-
ure and consideration for switching of ART (BIII).
Health care practitioners and health systems should initiate strat-
egies to monitor and improve entry into and retention in care
and ART adherence and to incorporate and analyze quality-of-
care indicators (CIII).
Management of multidrug resistance is complex and expert ad-
vice should be sought (BII).
aRatings of the strength of the recommendations and quality of evi-
dence are described in the eBox. The recommendations in Box 1 were
chosen because (1) the recommendation was entirely new compared
with the 2010 International AIDS Society–USA guidelines or (2) the
recommendation had changed in some substantial way, including
strength of grading, compared with the 2010 guidelines. The section
leaders reviewed and approved inclusion of appropriate recommen-
dations and the entire committee reviewed and approved Box 1.
CONCLUSIONS AND FUTURE 
DIRECTIONS
When HIV is allowed to replicate un-
inhibited by ART, resultant immune ac-
tivation and inflammation are associ-
ated not only with immune destruction 
and opportunistic infections but also in-
creased rates of cardiovascular, renal, 
hepatic, and neurologic diseases; ma-
lignancies; and other serious non-
AIDS diseases. Evidence from clinical 
trials, observational cohorts, and patho-
genesis studies all point toward the 
health benefits of earlier ART. Potent 
and tolerable treatment regimens now 
make durable viral suppression pos-
sible for most persons throughout the 
course of HIV infection. Clinical trial 
and ecological data likewise under-
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